PDCD1 and neoplasm: For example, unlike other tumors that respond to immune checkpoint blockade, ccRCC has a relatively low tumor mutational load, which is thought to drive T-cell infiltration19,43, and mutational burden in ccRCC is not associated with response to anti-PD-1 therapy15.